New Hope For Spinal Injury Patients?

18 August 1996

Rehabilitation could become a realistic outcome for thousands of patients with spinal cord injuries, according to a report published in Science (volume 273, page 510). There is no existing treatment that offers a complete regeneration of spinal cord function in humans.

However, this study, conducted by Henrich Cheng et al of the Karolinska Institute in Stockholm, Sweden, discovered that spinal lesions can now be regenerated in rats whose spinal cords have been completely severed, and that their paralysis can to some extent be reversed as a result of this pioneering work.

Once damage has been done to the spine, the nerve cells in the spine are unable to regrow as they are prevented from developing along the axon by chemicals such as neurite inhibitory factor, which is produced by the white matter in the spinal cord. As the nerves in this part of the body are part of the central nervous system, the innervation and stimulus for muscle movement in the rest of the body disappears, leaving the individual paralyzed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight